This study aimed to screen in vitro antitumour activity of the redox couple avarol/avarone against the human malignant glioma cell line U-251 MG for the first time. Compared both with avarol and positive controls used (temozolomide and doxorubicin), avarone was found to be the most active compound with IC50 value below 1 mu M (IC50 0.68 +/- 0.04 mu M, 96 h). Considerable less DNA damage in the cells treated with avarol and avarone vs. doxorubicin (105 & 123% vs. 299%, respectively; untreated U-251 MG cells were used as a control, 100%), coupled with no sign of cytotoxicity against the normal human foetal lung fibroblast MRC-5 cells (IC50 > 100 mu M), has actually pointed out the importance of this marine sesquiterpenoid quinone structure as a promising lead compound in development of novel brain chemotherapeutics. [GRAPHICS] .
Keywords:
the avarol scaffold / Dysidea avara / Brain tumours
TY - JOUR
AU - Pejin, Boris
AU - Tommonaro, Giuseppina
AU - Glumac, Miodrag
AU - Jakimov, Dimitar
AU - Kojić, Vesna
PY - 2018
UR - http://rimsi.imsi.bg.ac.rs/handle/123456789/1194
AB - This study aimed to screen in vitro antitumour activity of the redox couple avarol/avarone against the human malignant glioma cell line U-251 MG for the first time. Compared both with avarol and positive controls used (temozolomide and doxorubicin), avarone was found to be the most active compound with IC50 value below 1 mu M (IC50 0.68 +/- 0.04 mu M, 96 h). Considerable less DNA damage in the cells treated with avarol and avarone vs. doxorubicin (105 & 123% vs. 299%, respectively; untreated U-251 MG cells were used as a control, 100%), coupled with no sign of cytotoxicity against the normal human foetal lung fibroblast MRC-5 cells (IC50 > 100 mu M), has actually pointed out the importance of this marine sesquiterpenoid quinone structure as a promising lead compound in development of novel brain chemotherapeutics. [GRAPHICS] .
PB - Taylor & Francis Ltd, Abingdon
T2 - Natural Product Research
T1 - The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells
EP - 620
IS - 5
SP - 616
VL - 32
DO - 10.1080/14786419.2017.1327959
ER -
@article{
author = "Pejin, Boris and Tommonaro, Giuseppina and Glumac, Miodrag and Jakimov, Dimitar and Kojić, Vesna",
year = "2018",
abstract = "This study aimed to screen in vitro antitumour activity of the redox couple avarol/avarone against the human malignant glioma cell line U-251 MG for the first time. Compared both with avarol and positive controls used (temozolomide and doxorubicin), avarone was found to be the most active compound with IC50 value below 1 mu M (IC50 0.68 +/- 0.04 mu M, 96 h). Considerable less DNA damage in the cells treated with avarol and avarone vs. doxorubicin (105 & 123% vs. 299%, respectively; untreated U-251 MG cells were used as a control, 100%), coupled with no sign of cytotoxicity against the normal human foetal lung fibroblast MRC-5 cells (IC50 > 100 mu M), has actually pointed out the importance of this marine sesquiterpenoid quinone structure as a promising lead compound in development of novel brain chemotherapeutics. [GRAPHICS] .",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "Natural Product Research",
title = "The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells",
pages = "620-616",
number = "5",
volume = "32",
doi = "10.1080/14786419.2017.1327959"
}
Pejin, B., Tommonaro, G., Glumac, M., Jakimov, D.,& Kojić, V.. (2018). The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells. in Natural Product Research
Taylor & Francis Ltd, Abingdon., 32(5), 616-620.
https://doi.org/10.1080/14786419.2017.1327959
Pejin B, Tommonaro G, Glumac M, Jakimov D, Kojić V. The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells. in Natural Product Research. 2018;32(5):616-620.
doi:10.1080/14786419.2017.1327959 .
Pejin, Boris, Tommonaro, Giuseppina, Glumac, Miodrag, Jakimov, Dimitar, Kojić, Vesna, "The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells" in Natural Product Research, 32, no. 5 (2018):616-620,
https://doi.org/10.1080/14786419.2017.1327959 . .
